Systemic Inflammation Predicts All-Cause Mortality: A Glasgow Inflammation Outcome Study

Michael J. Proctor1*, Donald C. McMillan1, Paul G. Horgan1, Colin D. Fletcher2, Dinesh Talwar3, David S. Morrison3

1 Academic unit of Surgery, School of Medicine-University of Glasgow, Glasgow, United Kingdom, 2 Department of Clinical Biochemistry, Royal Infirmary, Glasgow, United Kingdom, 3 West of Scotland Cancer Surveillance Unit, University of Glasgow, Glasgow, United Kingdom

* m.proctor@nhs.net

Abstract

Introduction

Markers of the systemic inflammatory response, including C-reactive protein and albumin (combined to form the modified Glasgow Prognostic Score), as well as neutrophil, lymphocyte and platelet counts have been shown to be prognostic of survival in patients with cancer. The aim of the present study was to examine the prognostic relationship between these markers of the systemic inflammatory response and all-cause, cancer, cardiovascular and cerebrovascular mortality in a large incidentally sampled cohort.

Methods

Patients (n = 160 481) who had an incidental blood sample taken between 2000 and 2008 were studied for the prognostic value of C-reactive protein (>10 mg/l), albumin (>35 mg/l), neutrophil (>7.5×10⁹/l) lymphocyte and platelet counts. Also, patients (n = 52 091) sampled following the introduction of high sensitivity C-reactive protein (>3 mg/l) measurements were studied. A combination of these markers, to make cumulative inflammation-based scores, were investigated.

Results

In all patients (n = 160 481) C-reactive protein (>10 mg/l) (HR 2.71, p < 0.001), albumin (>35 mg/l) (HR 3.68, p < 0.001) and neutrophil counts (HR 2.18, p < 0.001) were independently predictive of all-cause mortality. These associations were also observed in cancer, cardiovascular and cerebrovascular mortality before and after the introduction of high sensitivity C-reactive protein measurements (>3 mg/l) (n = 52 091). A combination of high sensitivity C-reactive protein (>3 mg/l), albumin and neutrophil count predicted all-cause (HR 7.37, p < 0.001, AUC 0.723), cancer (HR 9.32, p < 0.001, AUC 0.731), cardiovascular (HR 4.03, p < 0.001, AUC 0.650) and cerebrovascular (HR 3.10, p < 0.001, AUC 0.623) mortality.
Conclusion

The results of the present study showed that an inflammation-based prognostic score, combining high sensitivity C-reactive protein, albumin and neutrophil count is prognostic of all-cause mortality.

Introduction

There is now good evidence that markers of the systemic inflammatory response, namely C-reactive protein and albumin using standard thresholds (termed the Glasgow Prognostic Score, GPS) have independent prognostic value in patients with a variety of cancers [1]. Similarly, neutrophils and lymphocytes using standard thresholds (termed the neutrophil lymphocyte ratio, NLR) have also been shown to have independent prognostic value [2]. Recently, in an effort to rationalise and consolidate the literature we have examined the relationship between these markers of the systemic inflammatory response, together with high sensitivity C-reactive protein measurements and platelet counts, and survival in more than 12,000 cancer patients. This resulted in an optimised score (termed the optimised Glasgow Prognostic Score, oGPS) composed of high sensitivity C-reactive protein (>3mg/l), albumin (<35g/l), neutrophil (>7.5 x 10⁹) and platelet (>400 x 10⁹) counts that had a superior predictive value when compared with the established GPS [3]. It remains to be determined whether such markers and scores also are associated with survival in other disease states.

It is therefore of interest that there have been numerous reports investigating the relationship between an elevated C-reactive protein concentration and increased risk of cardiovascular [4–6], cerebrovascular [5,7] and all-cause mortality [8,9]. There have also been occasional reports of other markers of the systemic inflammatory response, including albumin [10,11], neutrophil count [12], lymphocyte count [13,14] and platelet count [15] being associated with all-cause mortality.

Therefore, the aim of the present study was to examine the relationship between markers of the systemic inflammatory response and all-cause, cancer, cardiovascular and cerebrovascular mortality, in a large incidental cohort.

Materials and Methods

Study design

From the Glasgow Inflammation Outcome Study (GIOS) cohort previously described, patients in North Glasgow, who had a single blood sample taken for C-reactive protein and albumin were considered [16]. Only those patients who also had a differential white cell count available, including lymphocyte, neutrophil and platelet count were included. Patients were sampled incidentally between January 2000 and October 2008. The sample size was originally based on similar work investigating the association between C-reactive protein and all-cause survival [8]. If multiple samples had been taken during this time period, only the initial set was used. Only those patients undergoing blood sampling after the introduction of the routine measurement of high sensitivity C-reactive protein (1st of August 2006), were included in the analysis investigating the prognostic value of high sensitivity thresholds (≤5mg/l). As the presence of malignancy is known to be associated with activation of the systemic inflammatory response [16], all patients with a diagnosed malignancy any time prior to or within 14 days of blood sample were noted and this factor was included in the analysis. Whether the sample was taken
as an outpatient or inpatient was also noted. All malignancies were included except non-malignant melanoma skin cancers.

Patient outcome and mortality was established through linkage with the Information Services Division for Scotland (ISD). Deaths were classed as all-cause and further subdivided into cancer specific, cardiovascular and cerebrovascular. Patients were excluded if under the age of 16 years, demographic details were incomplete or if returned ISD fields were inaccurate or incomplete. Ethical approval was granted for the present study by the Research Ethics Committee, North Glasgow NHS Trust.

Methods

Patients with routine laboratory measurements of C-reactive protein, albumin and a differential white cell count, including neutrophil, lymphocyte and platelet counts were obtained by systematically searching the North Glasgow biochemical and haematological database systems. As previously reported, 223,303 patients were identified [16]. The limit of detection of C-reactive protein was a concentration of less than 5mg/l up to 1st of August 2006 and 0.05mg/l thereafter. Standardised thresholds for C-reactive protein (>10mg/l), neutrophil count (>7.5×10⁹/l), lymphocyte count (>3×10⁹/l) and platelet count (>400×10⁹/l) were studied. High sensitivity C-reactive protein threshold >3mg/l, previously reported to be associated with survival [17–20] and shown to be the optimal threshold in this cohort [3], was also studied. From previously published work on the present cohort, cumulative scores based on markers of the systemic inflammatory response, were reported to predict cancer outcomes [21]. These scores were simply composed of variables with similar hazard ratios that had previously been validated in cancer cohorts, including the mGPS comprising of C-reactive protein and albumin, as well as the addition of other haematological markers of the systemic inflammatory response including the constituents of a differential white cell count, in particular the neutrophil count, and a high sensitivity C-reactive protein measurement. In the present analysis a model was built up in a similar way for all-cause mortality [3]. Only components that were independently predictive of outcome were taken forward to be included in the final score. The benefit of using high sensitivity C-reactive protein measurements was also investigated by substituting the standard threshold (>10mg/L) with >3mg/L.

Patient outcome and mortality was established through linkage with the ISD for Scotland by exact matching surname, forename, sex and date of birth. If no match on surname then Daitch-Mokotoff followed by NYSIIS soundex algorithms were employed. On remaining unmatched cases, forenames and surnames were switched followed by matching on previous surnames, reversing gender, using first initial opposed to full forename and finally on surname gender and date of birth only. On all those not with exact matches a manual check on whether to include or exclude was taken. Of the 223,303 patients originally identified, 213,127 were successfully matched through the ISD linkage and 10,176 were not identified (5%). Of these matched patients, 160,481 patients had C-reactive protein and albumin as well as a complete differential white cell count. The presence of SMR01 records were used to determine whether a patient was sampled during a hospital admission as well as whether the patient had died. Hospital admission was defined as having been sampled during a continuous inpatient stay. SMRO6 records containing International Classification of Disease (ICD) codes were used to identify those with a diagnosis of cancer prior to, or within 14 days of blood sampling, as previously described [16]. Cancer related mortality was defined as ICD10 codes C00—C97, cardiovascular (ischaemic heart disease) related mortality was defined as ICD10 codes I20—I25 and cerebrovascular disease related mortality was defined as ICD10 codes I60—I69 and established through ISD. At the time of data collection, the ISD held complete SMR01 data on registered
deaths until May 2011. Survival was calculated from time of blood sample to date of death or censor date (31st of May 2011).

The Scottish Index of Multiple Deprivation (SIMD) 2006, as recommended by the ISD on behalf of NHS Scotland and the Scottish Government Department of Health, was used to measure deprivation [22]. The SIMD is a validated area-based measure of relative socio-economic circumstance that uses seven domains (current income; employment; health; education, skills and training; geographic access to services; housing; and crime) to score small areas (data zones). Scotland is divided into 6,505 data zones and these have been ranked from 1 (most deprived) to 6,505 (least deprived). These have further been divided into quintiles of the Scottish population; we used quintiles that range from 1 (least deprived) to 5 (most deprived).

Statistics

The relationships between patient demographics and outcome were analysed using the Pearson’s chi-square test. Cox proportional hazard model was used to analyse the relationship between patient demographics, hospital admission, the presence of cancer, C-reactive protein, albumin, neutrophil, lymphocyte and platelet counts. In those patients with a high sensitivity C-reactive protein measurement, the prognostic value of the combination of C-reactive protein, albumin and neutrophils, adjusted for age, sex, deprivation, hospital admission and the presence of cancer, was analysed using the Cox proportional hazard model and the Area Under the receiver operating characteristic Curve (AUC). During this analysis the proportionality assumptions in the Cox model were explored using a log minus log visual inspection and were found to be satisfactory. The relationship between the optimised Glasgow Prognostic Score and survival was assessed using the Kaplan-Meier log rank. A p value of <0.05 was considered to have statistical significance in the analysis. Analysis was performed using SPSS software (SPSS, Chicago, IL, USA).

Results

From GIOS cohort of 223 303 patients originally described [16], 209 148 (94%) were matched with a unique patient record in the ISD dataset. Of this group 160 481 fitted the inclusion criteria and had a differential white cell count available, including neutrophil, lymphocyte and platelet counts. Most patients were under 65 years of age (n = 103 779, 65%) Increasing age resulted in increasing mortality with malignancy being the predominant cause of death in all age groups (p<0.001). Most patients were female (n = 85 308, 53%) with significantly increased mortality from cerebrovascular disease (p<0.001) but decreased mortality from malignancy and ischaemic heart disease (both p<0.001) when compared to males. Forty four percent of patients (n = 71 156) were SIMD 5 (most deprived) with mortality levels generally increasing from malignancy, cerebrovascular disease and ischaemic heart disease observed with increasing deprivation. On follow up of all patients, there were 42 242 deaths in total of which 13 176 (31%) were cancer related, 6076 (14%) were cardiovascular related and 3638 (9%) were cerebrovascular related. The minimum follow up from blood sample for all patients was 31 months and the maximum 134 months (median follow up 69 months for survivors). The relationship between patient demographics, hospital admission, history of cancer, C-reactive protein (>10mg/l), albumin, neutrophil, lymphocyte and platelet counts and survival (n = 160 481) is shown in Table 1. Increasing age, male gender, increasing deprivation, hospital admission, history of cancer, high C-reactive protein (>10mg/l), neutrophil and platelet counts were independently associated with an increase in all-cause mortality (all p<0.001). Low albumin and lymphocyte counts were independently associated with an increase in all-cause mortality (all p<0.001). Increasing age, male gender, history of cancer, high C-reactive protein (>10mg/l),
Table 1. The relationship between patient demographics, markers of the systemic inflammatory response and mortality in an incidental cohort (n = 160481).

|                                | All-cause mortality | Cancer mortality | Cardiovascular mortality | Cerebrovascular mortality |
|--------------------------------|---------------------|------------------|--------------------------|---------------------------|
|                                | Deaths = 42 242     | Deaths = 13 176  | Deaths = 6076            | Deaths = 3638             |
|                                | Univariate          | Multivariate     | Univariate               | Multivariate              |
|                                | HR                  | p-value          | HR                       | p-value                   |
|                                | HR                  | p-value          | HR                       | p-value                   |
|                                | HR                  | p-value          | HR                       | p-value                   |
|                                | HR                  | p-value          | HR                       | p-value                   |
| Age                            |                     |                  |                          |                           |
| <65                            | 103 779 (65)        | 1                | 1                        | 1                         |
| 65–74                          | 26 969 (17)         | 4.00             | <0.001                   | 3.31                      |
|                               |                     |                  |                          | <0.001                    |
| >75                            | 23 716 (18)         | 8.27             | <0.001                   | 6.51                      |
|                               |                     |                  |                          | <0.001                    |
| Sex                            |                     |                  |                          |                           |
| Male                           | 75 173 (47)         | 1                | 1                        | 1                         |
|                               |                     |                  |                          | <0.001                    |
| Female                         | 85 308 (53)         | 0.86             | <0.001                   | 0.77                      |
|                               |                     |                  |                          | <0.001                    |
| SIMD                           |                     |                  |                          |                           |
| 1                              | 21 362 (13)         | 1                | 1                        | 1                         |
|                               |                     |                  |                          | <0.001                    |
| 2                              | 17 778 (11)         | 1.03             | 0.216                    | 1.11                      |
|                               |                     |                  |                          | <0.001                    |
| 3                              | 20 432 (13)         | 1.16             | <0.001                   | 1.20                      |
|                               |                     |                  |                          | <0.001                    |
| 4                              | 29 753 (19)         | 1.28             | <0.001                   | 1.30                      |
|                               |                     |                  |                          | <0.001                    |
| 5                              | 71 156 (44)         | 1.25             | <0.001                   | 1.36                      |
|                               |                     |                  |                          | <0.001                    |
| Hospital Admission             |                     |                  |                          |                           |
| No                             | 74 142 (46)         | 1                | 1                        | 1                         |
|                               |                     |                  |                          | <0.001                    |
| Yes                            | 86 339 (54)         | 1.75             | <0.001                   | 1.21                      |
|                               |                     |                  |                          | <0.001                    |
| History of Cancer              |                     |                  |                          |                           |
| None                           | 139 089 (87)        | 1                | 1                        | 1                         |
|                               |                     |                  |                          | <0.001                    |
| Present                        | 21 401 (13)         | 3.40             | <0.001                   | 2.13                      |
|                               |                     |                  |                          | <0.001                    |
| C-reactive protein             |                     |                  |                          |                           |
| <10mg/l                        | 94 544 (59)         | 1                | <0.001                   | 1                         |
|                               |                     |                  |                          | <0.001                    |
| >10mg/l                        | 65 937 (41)         | 2.71             | <0.001                   | 1.60                      |
|                               |                     |                  |                          | <0.001                    |
| Albumin                        |                     |                  |                          |                           |
| >35mg/l                        | 135 087 (84)        | 1                | <0.001                   | 1                         |
|                               |                     |                  |                          | <0.001                    |
| <35mg/l                        | 25 394 (216)        | 3.68             | <0.001                   | 2.02                      |
|                               |                     |                  |                          | <0.001                    |
| Neutrophil count               |                     |                  |                          |                           |
| <7.5×10^9/l                    | 127 736 (89)        | 1                | <0.001                   | 1                         |
|                               |                     |                  |                          | <0.001                    |
| >7.5×10^9/l                    | 32 745 (20)         | 2.18             | <0.001                   | 1.49                      |
|                               |                     |                  |                          | <0.001                    |
| Lymphocyte count               |                     |                  |                          |                           |
| >3×10^10/l                     | 12 782 (8)          | 1                | <0.001                   | 1                         |
|                               |                     |                  |                          | <0.001                    |
| <3×10^10/l                     | 147 939 (92)        | 1.87             | <0.001                   | 1.21                      |
|                               |                     |                  |                          | <0.001                    |
| Platelet count                 |                     |                  |                          |                           |
| <400×10^9/l                    | 143 431 (89)        | 1                | <0.001                   | 1                         |
|                               |                     |                  |                          | <0.001                    |
| >400×10^9/l                    | 17 050 (11)         | 1.64             | <0.001                   | 1.07                      |
|                               |                     |                  |                          | <0.001                    |
neutrophil and platelet counts were independently associated with an increase in cancer specific mortality (all \( p < 0.001 \)). Low albumin and lymphocytes were independently associated with an increase in cancer specific mortality (all \( p < 0.001 \)). Increasing age, male gender, increasing deprivation, hospital admission, history of cancer, high C-reactive protein (>10mg/l), neutrophil and platelet counts were independently associated with an increase in cardiovascular mortality (all \( p = 0.001 \)). Low albumin was independently associated with an increase in cardiovascular mortality (all \( p < 0.001 \)). Increasing age, hospital admission, no history of cancer, high C-reactive protein (>10mg/l), neutrophil count were independently associated with an increase in cerebrovascular mortality (all \( p < 0.001 \)). Low albumin was independently associated with an increase in cerebrovascular mortality (all \( p < 0.001 \)).

The relationship between patient demographics, hospital admission, history of cancer, C-reactive protein (>3mg/l), albumin, neutrophil, lymphocyte and platelet counts and survival in patients with a differential white cell count following the introduction of high sensitivity C-reactive protein (\( n = 52\,091 \)) is shown in Table 2. Increasing age, male gender, hospital admission, history of cancer, high C-reactive protein (>3mg/l), neutrophil and platelet counts were independently associated with an increase in all-cause mortality (all \( p < 0.001 \)). Low albumin and lymphocyte counts were independently associated with an increase in all-cause mortality (all \( p < 0.001 \)). Increasing age, male gender, history of cancer, high C-reactive protein (>3mg/l) and neutrophil counts were independently associated with an increase in cancer mortality (all \( p < 0.001 \)). Low albumin and lymphocyte counts were independently associated with an increase in cancer mortality (all \( p < 0.001 \)). Increasing age, male gender, hospital admission, history of cancer, high C-reactive protein (>3mg/l) and neutrophil counts were independently associated with an increase in cardiovascular mortality (all \( p < 0.001 \)). Low albumin was independently associated with an increase in cardiovascular mortality (\( p < 0.001 \)). Increasing age, hospital admission, history of cancer, high C-reactive protein (>3mg/l) and neutrophil counts were independently associated with an increase in cerebrovascular mortality (all \( p < 0.05 \)). Low albumin was independently associated with an increase in cerebrovascular mortality (\( p < 0.05 \)).

As C-reactive protein, albumin and neutrophils were consistently predictive of all-cause, cancer, cardiovascular and cerebrovascular specific mortality, these were taken forward to examine the prognostic value of their combination. These items were not individually weighted as they had similar predictive value in multivariate analysis and the focus of this process was to provide a simple score easily adopted in the clinical setting. The relationship between cumulative markers of the systemic inflammatory response (including high sensitivity C-reactive protein, albumin and neutrophil count) and mortality (\( n = 52\,091 \)) is shown in Table 3. All combinations of these systemic inflammatory markers were predictive of all-cause, cancer, cardiovascular and cerebrovascular specific survival (all \( p < 0.01 \)) independent of age, sex deprivation, hospital admission and the presence of cancer (Fig. 1). The Kaplan-Meier plot, for a score of 3, shows an initial steep curve that subsequently does not diverge from the curves of a score of 0–2. This suggests that systemic inflammation is particularly predictive of early all-cause mortality. The combination of C-reactive protein (>10mg/L), albumin and neutrophil count had an area under the Receiver Operator Curve (ROC) curve for all-cause mortality of 0.720 (95% CI 0.714–0.727, \( p < 0.001 \)), cancer mortality of 0.728 (95% CI 0.718–0.737, \( p < 0.001 \)), cardiovascular mortality of 0.645 (95% CI 0.627–0.664, \( p < 0.001 \)) and cerebrovascular mortality of 0.612 (95% CI 0.589–0.636, \( p < 0.001 \)). The combination of C-reactive protein (>3mg/L), albumin and neutrophil count had an area under the curve for all-cause mortality of 0.723 (95% CI 0.717–0.729, \( p < 0.001 \)), cancer mortality of 0.731 (95% CI 0.722–0.740, \( p < 0.001 \)), cardiovascular mortality of 0.650 (95% CI 0.633–0.668, \( p < 0.001 \)) and cerebrovascular mortality of 0.623 (95% CI 0.599–0.646, \( p < 0.001 \)). The area under the curve represent the full model for each of the three outcomes.
Table 2. The relationship between patient demographics, markers of the systemic inflammatory response (including high sensitivity C-reactive protein) and mortality in an incidental cohort (n = 52 091).

|                      | All-cause mortality | Cancer mortality | Cardiovascular mortality | Cerebrovascular mortality |
|----------------------|---------------------|------------------|--------------------------|--------------------------|
|                      | Deaths = 8243       | Deaths = 3480    | Deaths = 929             | Deaths = 553             |
|                      | Univariate          | Multivariate     | Univariate               | Multivariate             |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      | HR                  | p-value          | HR                      | p-value                  |
|                      |                    |                  |                          |                          |
|                      | n (%)               |                  | 1                        | 1                        |
| Age                  | 36 834 (71)         | 1                |                          |                          |
|                      | <65/                | 1                |                          |                          |
|                      | 65–74               | 4.28 <0.001 2.95 <0.001 4.36 <0.001 2.12 <0.001 6.26 <0.001 5.73 <0.001 7.75 <0.001 7.39 <0.001 |
|                      | >75                 | 8.10 <0.001 5.24 <0.001 4.82 <0.001 2.20 <0.001 14.36 <0.001 13.18 <0.001 24.31 <0.001 22.20 <0.001 |
| Sex                  | Male                | 25 411 (49)      | 1                        | 2                        |
|                      | 2.95 <0.001 4.36 <0.001 4.82 <0.001 2.20 <0.001 14.36 <0.001 13.18 <0.001 24.31 <0.001 22.20 <0.001 |
|                      | Female              | 26 680 (51)      | 0.87 0.77                | 0.86 0.76                |
|                      | 0.72 0.61           | 1.18             |                          |                          |
| SIMD                 | 6943 (13)           | 1                |                          |                          |
|                      | 2.95 <0.001 4.36 <0.001 4.82 <0.001 2.20 <0.001 14.36 <0.001 13.18 <0.001 24.31 <0.001 22.20 <0.001 |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
|                      | 1.97 0.001          | 1.33             |                          |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
| Hospital Admission   | 23 616 (49)         | 1                | 1                        |                          |
|                      | 1.76 <0.001 1.16 <0.001 1.56 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 |
| History of Cancer    | 28 475 (55)         | 1.76 <0.001 1.16 <0.001 1.56 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 |
| C-reactive protein   | 20 917 (40)         | 1                | 1                        |                          |
|                      | 4.74 <0.001 2.49 <0.001 12.75 <0.001 8.00 <0.001 1.57 <0.001 0.74 0.002 1.78 <0.001 0.77 0.032 |
|                      | 3.50 <0.001 1.55 1.58 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 |
|                      | 1.01 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
| Albumin              | 20 917 (40)         | 1                |                          |                          |
|                      | 4.74 <0.001 2.49 <0.001 12.75 <0.001 8.00 <0.001 1.57 <0.001 0.74 0.002 1.78 <0.001 0.77 0.032 |
|                      | 3.50 <0.001 1.55 1.58 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 |
|                      | 1.01 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
| Neutrophil count     | 20 917 (40)         | 1                |                          |                          |
|                      | 4.74 <0.001 2.49 <0.001 12.75 <0.001 8.00 <0.001 1.57 <0.001 0.74 0.002 1.78 <0.001 0.77 0.032 |
|                      | 3.50 <0.001 1.55 1.58 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 |
|                      | 1.01 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
| Lymphocyte count     | 20 917 (40)         | 1                |                          |                          |
|                      | 4.74 <0.001 2.49 <0.001 12.75 <0.001 8.00 <0.001 1.57 <0.001 0.74 0.002 1.78 <0.001 0.77 0.032 |
|                      | 3.50 <0.001 1.55 1.58 <0.001 0.96 0.229 1.82 <0.001 1.29 <0.001 2.31 <0.001 1.74 <0.001 |
|                      | 1.01 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
|                      | 1.07 0.14           | 1.23             | 0.133                    |
| Platelet count       | 48 393 (91)         | 2.05 1.16 2.70 1.54 1.39 0.82 1.66 1.01 | | 0.950 |

doi:10.1371/journal.pone.0116206.t002
The results of the present study show that, in a large incidentally sampled cohort of patients ($n = 160,481$), a number of routinely measured, objective markers of the systemic inflammatory response were independently associated with all-cause mortality. Furthermore, C-reactive protein, albumin and neutrophils were confirmed to have independent prognostic value in patients dying of cancer as well as cardiovascular and cerebrovascular disease. These results implicate the activation of the systemic inflammatory response as a key factor in the shortened survival in common lethal disease states.

The results of the present study are consistent with previous work using individual markers of the systemic inflammatory response to predict all-cause mortality [8–12] and goes further to demonstrate that the combination of C-reactive protein, albumin and neutrophils can further improve the prognostic value of the systemic inflammatory response. Furthermore, these associations remained following adjustment for hospital admission and a previous diagnosis of cancer, events likely to be associated with raised inflammatory markers and reduced survival. It was of interest that a history of cancer, in those dying from cardiovascular and cerebrovascular disease, was positively associated with mortality in univariate survival analysis but negatively associated in multivariate analysis. The basis of this observation is not clear, however, it is worth noting that age was a dominant factor associated with outcome, in particular for cardiovascular and cerebrovascular mortality. Moreover, when all factors were entered into multivariate analysis, the hazard ratios of a number of variables including C-reactive protein and albumin, as well as neutrophil, lymphocyte and platelet counts were reduced. Therefore, it may be that a history of cancer is acting as a surrogate marker for age during univariate analysis with this effect being corrected for in multivariate regression. A similar interaction may explain the observed relationship between platelet count and cardiovascular mortality, as it was noted that as age increased, so did the percentage of patients with a high platelet count ($<65$ 10%, $65–75$ 12%, $>75$ 13%).

It was also of interest that, for similar incremental increases in individual markers of the systemic inflammatory response, the hazard ratios were greater for cancer mortality, when compared to cardiovascular and cerebrovascular mortality. These results are consistent with those reported by Marsik and co-workers [8] in a hospital based cohort of 274,515 patients using C-reactive protein as a marker of the systemic inflammatory response. The basis of this strong

| Table 3. The relationship between cumulative markers of the systemic inflammatory response (including high sensitivity C-reactive protein) and mortality in an incidental cohort: Adjusted for age, sex, deprivation, hospital admission and the presence of cancer ($n = 52,091$). |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                | All-cause mortality              | Cancer mortality                | Cardiovascular mortality         |
|                                |                                  |                                  | Cerebrovascular mortality        |
|                                | Deaths = 8243                    | Deaths = 3480                    | Deaths = 929                     | Deaths = 553                     |
| n (%)                          | HR p-value AUC                   | HR p-value AUC                   | HR p-value AUC                   | HR p-value AUC                   |
| 0 26,603 (51)                  | 1 0.720                          | 1.99 <0.001                     | 1.66 <0.001                     | 1.53 <0.001                     |
| CRP > 10mg/l 1 13,734 (26)     | 1.92 <0.001                     | 4.27 <0.001                     | 2.67 <0.001                     | 1.76 <0.001                     |
| +Albumin >35g/L 2 8635 (17)    | 3.45 <0.001                     | 7.95 <0.001                     | 3.49 <0.001                     | 2.50 <0.001                     |
| +Neutrophils >7.5×10⁹/l 3 3119 (6) | 6.45 <0.001                  | 7.95 <0.001                     | 3.49 <0.001                     | 2.50 <0.001                     |
| 0 17,542 (34)                  | 1 0.723                          | 1.94 <0.001                     | 1.62 <0.001                     | 1.40 0.006                      |
| hs-CRP >3mg/l 1 19,880 (38)    | 1.76 <0.001                     | 1.94 <0.001                     | 1.62 <0.001                     | 1.40 0.006                      |
| + Albumin >35g/L 2 11,158 (21) | 3.58 <0.001                     | 4.44 <0.001                     | 2.92 <0.001                     | 1.90 <0.001                     |
| + Neutrophils >7.5×10⁹/l 3 3511 (7) | 7.37 <0.001                  | 9.32 <0.001                     | 4.03 <0.001                     | 3.10 <0.001                     |
association between the systemic inflammatory response and cancer mortality, when compared with cardiovascular and cerebrovascular mortality, is not clear but highlights the potential of the systemic inflammatory response as a therapeutic oncological target [23,24].

In the present study the variables chosen, and the method of their combination for a cumulative score, was based on previous work establishing the prognostic value of the systemic inflammatory response in patients with cancer [3]. It was noted that while the addition of a high
sensitivity C-reactive protein did little to improve the cumulative model's AUC, it did illustrate the value of a C-reactive protein threshold (<3mg/L) commonly used in cardiovascular disease and appeared to better differentiate those patients that were likely to do particularly well. The present Receiver Operator Curve analysis demonstrated relatively wide confidence intervals as well as overlap between the curves for the different combinations of variables and it is possible that these do not represent the optimum combination in cardiovascular and cerebrovascular disease. Nevertheless, the present analysis does produce a functional, easy to use, clinical score that highlights the importance of the systemic inflammatory response in disease states including cancer, cardiovascular and cerebrovascular disease.

The basis of the independent prognostic value of C-reactive protein, albumin and neutrophil count over all disease states (and platelets in cancer) is likely to be complex. However, these factors are known to be involved with regulation of the immune/inflammatory response and in particular the innate immune/inflammatory response. Therefore, it may be hypothesised that the complementary prognostic value of these factors reflects an upregulation of the innate immune/inflammatory responses The consistency of observations across different tumour types and now different disease states suggests that this hypothesis is worthy of further study.

With reference to cancer, the role of markers of the systemic inflammatory response in predicting outcome has become recognised [1,2] and the clinical utility of combining such markers with tumour based factors to provide improved patient counselling and personalised treatment is becoming increasingly recognised [25–27]. The present results provide a framework for the further development of a paradigm that uses both patient and tumour based objective factors to predict patient prognosis.

With reference to cardiovascular and cerebrovascular disease, the prognostic value of C-reactive protein has become increasingly recognised [28]. Indeed, high sensitivity C-reactive protein has been recommended for use in the risk stratification of cardiovascular disease in certain patient groups [29]. Therefore, the present results also provide further evidence for the clinical utility of systemic inflammation-based scoring systems in predicting outcome in cardiovascular and cerebrovascular disease. Indeed, this approach with C-reactive protein and albumin as core factors, has recently been validated in the NHANES III cohort [30] and while the AUCs in the present cohort were around 0.65, this was an improvement on using a single variable alone.

There are striking parallels between the present systemic inflammatory response and the phenomenon of allopathic (also allostatic) load. This ‘wear and tear’ occurs as a consequence of the repeated activation of compensatory physiological mechanisms to chronic stress, including the hyperactivation of the hypothalamic-pituitary axis [31]. As such, the allostatic load can significantly accelerate the ageing process with this being proposed as a mechanism by which deprivation impacts on life expectancy. Therefore, it can be readily envisaged that the systemic inflammatory response may play a key role in the allostatic load paradigm given that measures of the systemic inflammatory response were directly associated with increasing levels of deprivation in the present study. Indeed, it was recently reported that increased physical activity was associated with lower inflammatory scores and allostatic load [32]. These associations are worthy of further study.

The present cohort study has a number of limitations. The patients were selected on the basis that measurements of C-reactive protein, albumin and a differential white cell count had been performed and were therefore not necessarily representative of all patients treated in the North Glasgow area. It is also recognised that the Glasgow based population has reduced life expectancy when compared to the rest of Europe and the present cohort may have had high levels of concurrent morbidity causing derangement of the variables studied. It is also recognised that while the SIMD has been used in an attempt to control for these confounding factors, this may not have been fully effective, and there remains the possibility of bias.
In summary, a number of markers of the systemic inflammatory response, reflecting an optimised Glasgow Prognostic Score, have prognostic utility not only in cancer, but also in cardiovascular and cerebrovascular disease survival. Further work to validate such findings in other large cohorts is warranted.

Acknowledgments
The authors would like to thank the hard work and assistance of Mr Billy Sloan.

Author Contributions
Conceived and designed the experiments: MP DCM DSM PGH DT. Performed the experiments: MP DSM CF. Analyzed the data: MP DCM PGH. Contributed reagents/materials/analysis tools: DSM CF. Wrote the paper: MP DCM DSM PGH.

References
1. McMillan DC (2012) The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat.Rev. 39:534–40. doi:10.1016/j.ctrv.2012.08.003 PMID: 22995477
2. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, et al. (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev. Oncol.Hematol. 88:218–30. doi: 10.1016/j.critrevonc.2013.03.010 PMID: 23602134
3. Proctor MJ, Horgan PG, Talwar D, Fletcher CD, Morrison DS, et al. (2013) Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study. Cancer 119:2325–32. doi:10.1002/cncr.28018 PMID: 23575969
4. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI (1996) Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur.Heart J. 17:1345–9. PMID:8880019
5. den Hertog HM, van Rossum JA, van der Worp HB, van Gemert HM, de Jonge R, et al. (2009) C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J.Neurol. 256:2003–8.
6. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, et al. (2013) Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events After an Acute Coronary Syndrome in the MIRACL Study. J. Am.Heart Assoc. 2:e003103. doi:10.1161/JAHA.112.003103 PMID: 23525424
7. Di Napoli M, Papa F, Boccola V (2001) C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32:917–24. PMID: 11283392
8. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, et al. (2008) C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin.Chem. 54:343–9. PMID:18156283
9. Zacho J, Tybjerg-Hansen A, Nordestgaard BG (2010) C-reactive protein and all-cause mortality—the Copenhagen City Heart Study. Eur.Heart J. 31:1624–32. doi:10.1093/eurheartj/ehq103 PMID: 20423919
10. Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J.Clin.Epidemiol. 50:693–703.
11. Grimm G, Haslacher H, Kampitsch T, Endler G, Marsik C, et al. (2009) Sex differences in the association between albumin and all-cause and vascular mortality. Eur.J.Clin.Invest. 39:860–5. doi: 10.1111/j.1365-2362.2009.02189.x PMID: 19645741
12. Gillum RF, Mussolino ME, Madans JH (2005) Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Am.Epidemiol. 15:266–71. PMID: 15780773
13. Acanfora D, Gheorghiade M, Trojano L, Furgi G, Pasini E, et al. (2001) Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. Am.Heart J. 142:167–73. PMID: 11431674
14. Phillips AC, Carroll D, Gale CR, Drayson M, Batty GD (2011) Lymphocyte cell counts in middle age are positively associated with subsequent all-cause and cardiovascular mortality. QJM. 104:319–24. doi: 10.1093/qjmed/hcq199 PMID: 21051481
15. Sokunbi DO, Wadhwa NK, Suh H (1994) Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis. Adv.Perit.Dial. 10:77–80. PMID: 7999869

16. Proctor MJ, Talwar D, Balmar SM, O’Reilly DS, Foulis AK, et al. (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br.J.Cancer 103:870–6. doi:10.1038/sj.bjc.6605855 PMID: 20717110

17. Ridker PM (2003) Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 108:e81–e85. PMID: 14504253

18. Ridker PM (2008) High-sensitivity C-reactive protein as a predictor of all-cause mortality: implications for research and patient care. Clin.Chem. 54:234–7. doi:10.1373/clinchem.2007.099465 PMID: 18223130

19. Lee S, Choe JW, Kim HK, Sung J (2011) High-sensitivity C-reactive protein and cancer. J.Epidemiol. 21:161–8. PMID: 21368452

20. Ko YJ, Kwon YM, Kim KH, Choi HC, Chun SH, Yoon HJ, et al. (2012) High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol.Biomarkers Prev. 21:2076–86. doi:10.1158/1055-9965.EPI-12-0611 PMID: 23136255

21. Proctor MJ, Morrison DS, Talwar D, Balmar SM, Fletcher CD, et al. (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur.J.Cancer 47:2633–41. doi:10.1016/j.ejca.2011.03.028 PMID: 21724383

22. Bishop J, Clark D, Harris V, Stockton D, Sutton M (2004) Deprivation and Urban Rural Measurements in ISD. Summary Report. Edinburgh, ISD Geography, Population, Census and Deprivation Group.

23. McMillan DC (2013) Cancer and systemic inflammation: stage the tumour and stage the host. Br.J.Cancer 109:529. doi:10.1038/bjc.2013.418 PMID: 23921279

24. Roxburgh CS, McMillan DC (2014) Cancer and systemic inflammation: treat the tumour and treat the host. Br.J.Cancer 110:1409–12. doi:10.1038/bjc.2014.90 PMID: 24548867

25. Inoue Y, Iwata T, Okugawa Y, Kawamoto A, Hiro J, et al. (2013) Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology 84:100–7. doi:10.1159/000343822 PMID: 23147449

26. Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, et al. (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU.Int. 108:1800–5. doi:10.1111/j.1464-410X.2011.10234.x PMID: 21507193

27. Lamb GW, Alchison M, Ramsey S, Housley SL, McMillan DC (2012) Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br.J.Cancer 106:279–83. doi:10.1038/bjc.2011.556 PMID: 22166802

28. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N.Engl.J.Med. 367:1310–20. doi:10.1056/NEJMoa1107477 PMID: 23034020

29. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, et al. (2010) 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J.Am.Coll.Cardiol. 56:e50–103. doi:10.1016/j.jacc.2010.09.001 PMID: 21144964

30. Van Hemelrijck M, Eichholzer M, Faeh D, Rohrmann S (2012) Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III. BMC.Public Health 12:895. doi: 10.1186/1471-2458-12-895 PMID: 23092358

31. Maestripieri D, Hoffman CL (2011) Chronic stress, allostatic load, and aging in nonhuman primates. Dev.Psychopathol. 23:1187–95. doi: 10.1017/S0954579411000551 PMID: 22018089

32. Gay JL, Salinas JJ, Buchner DM, Mirza S, Kohl HW, et al. (2013) Meeting Physical Activity Guidelines is Associated with Lower Allostatic Load and Inflammation in Mexican Americans. J.Immigr.Minor. Health epub ahead of print.